Search
Guretolimod
go.drugbank.com/drugs/DB21487InvestigationalGuretolimod is under investigation in clinical trial NCT03416335 (A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile).
Amsilarotene
go.drugbank.com/drugs/DB21085InvestigationalAmsilarotene is under investigation in clinical trial NCT00687596 (Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
Selnoflast
go.drugbank.com/drugs/DB21522InvestigationalSelnoflast is under investigation in clinical trial NCT05924243 (A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic
Hexamethonium
go.drugbank.com/drugs/DB08960ExperimentalA nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.
Human Embryonic Stem Cell-derived M Cell
go.drugbank.com/drugs/DB15734InvestigationalIMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation.
Exagamglogene autotemcel
go.drugbank.com/drugs/DB15572ApprovedInvestigational[L49231] It is the first CRISPR-based gene editing therapy to be approved in the United States.
Octacosanol
go.drugbank.com/drugs/DB11220InvestigationalNutraceuticalThis high–molecular-weight organic compound is the main component of a natural product wax extracted from plants [A27245]. 1-octacosanol is reported to possess cholesterol-lowering effects, antiaggregatory
GEM-231
go.drugbank.com/drugs/DB05798InvestigationalMonoclonal antibodies are made in the laboratory and can locate and bind to cancer cells.
Bafilomycin A1
go.drugbank.com/drugs/DB06733ExperimentalThe bafilomycins refer to a category of toxic macrolide antibiotics that are derivatives of Streptomyces griseus.
Ibudilast
go.drugbank.com/drugs/DB05266InvestigationalIbudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume